Patrick Miles Sells 6,687 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles sold 6,687 shares of Alphatec stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $12.00, for a total transaction of $80,244.00. Following the transaction, the chief executive officer now directly owns 5,501,715 shares in the company, valued at approximately $66,020,580. This represents a 0.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Alphatec Stock Down 5.7 %

Shares of ATEC stock opened at $11.01 on Friday. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $17.34. The firm’s fifty day moving average price is $9.92 and its two-hundred day moving average price is $8.10. The firm has a market capitalization of $1.56 billion, a P/E ratio of -8.60 and a beta of 1.41.

Institutional Investors Weigh In On Alphatec

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Lighthouse Investment Partners LLC increased its stake in Alphatec by 257.5% in the 2nd quarter. Lighthouse Investment Partners LLC now owns 208,594 shares of the medical technology company’s stock valued at $2,180,000 after buying an additional 150,244 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in Alphatec by 11.3% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company’s stock valued at $16,280,000 after buying an additional 297,850 shares during the last quarter. Barclays PLC increased its stake in Alphatec by 362.3% in the 3rd quarter. Barclays PLC now owns 170,546 shares of the medical technology company’s stock valued at $948,000 after buying an additional 133,653 shares during the last quarter. Franklin Resources Inc. increased its stake in Alphatec by 299.3% in the 3rd quarter. Franklin Resources Inc. now owns 64,450 shares of the medical technology company’s stock valued at $343,000 after buying an additional 48,308 shares during the last quarter. Finally, AlphaCentric Advisors LLC acquired a new stake in Alphatec in the 3rd quarter valued at $2,057,000. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on ATEC shares. Needham & Company LLC lifted their price target on shares of Alphatec from $13.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. Barclays lifted their price target on shares of Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Alphatec in a report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Alphatec has an average rating of “Moderate Buy” and a consensus price target of $17.56.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.